Loading... Please wait...
Sort by:

 

firstview-jpg.jpgFirstView reports deliver unique insight into current and future pharma market dynamics through quantitative surveys with physicians. With the ability to query a 1-million strong online physician community worldwide, FirstView provides essential data to support effective decision making in major disease areas and on key industry issues.

  • Medical Affairs Reputations: Growth Hormone Deficiency (US)
    Learn More Medical Affairs Reputations: Growth Hormone Deficiency (US)
    Two Medical Affairs teams lead the market. Can your team learn from their success? Two medical affairs teams have the lead in the US growth hormone deficiency (GHD) treatment market, with the third placed team not far...
  • Market Access Impact: Type 2 Diabetes Mellitus (EU5) 2016
    Learn More Market Access Impact: Type 2 Diabetes Mellitus (EU5) 2016
    How are market barriers impacting the host of European T2DM brands? It’s a fact of life that non-clinical constraints such as cost, availability and administration are influencing prescribing trends for Type 2...
  • Market Access Impact: Multiple Sclerosis (EU5)
    Learn More Market Access Impact: Multiple Sclerosis (EU5)
    Prescription barriers boost market share for 6 of the 10 brands we surveyed. Is yours losing out? In the highly competitive multiple sclerosis (MS) treatment market, prescription barriers helped 6 of the 10 brands we...
  • Market Access Impact: Multiple Sclerosis (US)
    Learn More Market Access Impact: Multiple Sclerosis (US)
    Which MS drug gets the biggest market share bump when doctors can’t prescribe rivals? In the highly competitive multiple sclerosis (MS) treatment market, prescription barriers helped 5 of the 10 brands we surveyed...
  • Market Access Impact: Asthma/COPD (EU5) 2016
    Learn More Market Access Impact: Asthma/COPD (EU5) 2016
    How are market barriers impacting market share for the leading asthma/COPD brands? Three brands top the list in Europe as most prescribed treatments for asthma and COPD, but are these the preferred options or are market...
  • Market Access Impact: Asthma/COPD (US) 2016
    Learn More Market Access Impact: Asthma/COPD (US) 2016
    Are market barriers helping or hindering your asthma/COPD brand’s performance? Three brands top the list in the US as the most prescribed treatments for asthma and COPD, but are these the preferred options or are...
  • Medical Affairs Reputations T2DM (EU5)
    Learn More Medical Affairs Reputations T2DM (EU5)
    Fierce competition in T2DM medical affairs. Can the top two teams hold onto their lead? Two medical affairs teams lead in the EU5 type 2 diabetes mellitus (T2DM) market, but for how long? Competition is fierce, and a...
  • Medical Affairs Reputations T2DM (US)
    Learn More Medical Affairs Reputations T2DM (US)
    Two medical affairs teams are way ahead. Can your team learn from their success? Two medical affairs teams have taken a big lead in the US type 2 diabetes mellitus (T2DM) market. Are they delivering the services doctors...
  • Medical Affairs Reputations: Melanoma (EU5)
    Learn More Medical Affairs Reputations: Melanoma (EU5)
    Top marks from oncologists show medical affairs push is paying off for immunotherapies In the EU5 Melanoma treatment market, one brand’s medical affairs team is reaching more oncologists—and earning...
  • Medical Affairs Reputations: Melanoma (US)
    Learn More Medical Affairs Reputations: Melanoma (US)
    Top marks from oncologists show medical affairs push is paying off for immunotherapies In the EU5 Melanoma treatment market, one brand’s medical affairs team is reaching more oncologists—and earning...
  • Medical Affairs Reputations: Multiple Sclerosis (EU5)
    Learn More Medical Affairs Reputations: Multiple Sclerosis (EU5)
    MS medical affairs: oral therapies outperforming in Europe. How does your team measure up? In Europe’s Multiple Sclerosis (MS) market, medical affairs teams for oral therapies outperform their platform-therapy...
  • Medical Affairs Reputations: Multiple Sclerosis (US)
    Learn More Medical Affairs Reputations: Multiple Sclerosis (US)
    MS medical affairs: oral therapies outperforming in the US. How does your team measure up? In the US multiple sclerosis (MS) market, medical affairs teams for oral therapies outperform their platform-therapy...
  • Market Access Impact: Growth Hormone Deficiency (US)
    Learn More Market Access Impact: Growth Hormone Deficiency (US)
    GHD: Has one brand found the winning market access strategy in the US? Market barriers affect nearly 40% of growth hormone prescriptions in the US, and most brands lose market share because of them. But one brand has...
  • Market Access Impact: Growth Hormone Deficiency (EU5)
    Learn More Market Access Impact: Growth Hormone Deficiency (EU5)
    GHD: Has one brand found the winning market access strategy in Europe? Market barriers affect nearly 25% of growth hormone prescriptions in Europe, costing most brands market share. But one brand’s efforts to...
  • Medical Affairs Reputations: HIV (US)
    Learn More Medical Affairs Reputations: HIV (US)
    HIV: Hard work is paying off for the top 2 medical affairs teams in the US. How is your team doing? In the past 6 months, the medical affairs teams for two leading HIV treatments reached more doctors than any other...
  • Medical Affairs Reputations: HIV (EU5)
    Learn More Medical Affairs Reputations: HIV (EU5)
    HIV: Hard work is paying off for the top 2 medical affairs teams in Europe. How is your team doing? In the past 6 months, the medical affairs teams for two leading HIV treatments reached up to 91% of the doctors we...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved